RAPS Learning Portal will be under maintenance on 12 June 2026 between 10 PM - 12 AM ET. Learning Portal functionality and profile access may be unavailable during this window.
We apologize for any inconvenience caused during this time.
Leaders from the House and Senate health committees wrote to Acting FDA Commissioner Janet Woodcock on Friday after the agency missed the 15 January deadline to transmit the commitment letter for the next iteration of the Medical Device User Fee Amendments (MDUFA V) to Congress.
The letter, signed by Senate Health, Education, Labor and Pensions committee Chair Patty Murray (D-WA) and Ranking Member Richard Burr (R-NC), as well as House Energy & Commerce committee Chair Frank Pallone (D-NJ) and Ranking Member Cathy McMorris Rodgers (R-WA), calls on FDA and industry to brief Congress on the status of the negotiations and the expected timeline for the process by 9 February.
“It is important that Congress have sufficient time to review each commitment letter and to evaluate the agreements,” the lawmakers wrote. “The FDA and medical device industry’s significant delay in transmitting the MDUFA commitment letter jeopardizes our ability to thoroughly review the commitments under the letter.”
Last month, FDA transmitted the final commitment letters for its user fee programs for prescription drugs, generic drugs and biosimilars (PDUFA, GDUFA, and BsUFA) to Congress after months of negotiation with industry. Each of the user fee programs is set to expire at the end of this fiscal year unless they are reauthorized.
Formal meetings between FDA and industry on MDUFA reauthorization have also stalled, with the last industry discussion taking place in June 2021.
The House Energy & Commerce committee also announced last week that it will kick off the legislative process for the user fee reauthorization this Thursday, with a hearing on PDUFA, GDUFA, and BsUFA reauthorization.
The Pharmaceuticals and Medical Devices Agency (PMDA) published guidance on using a weight of evidence (WOE) approach to assessing the toxicity of monoclonal antibodies in Japan.
Industry groups have asked the US Food and Drug Administration (FDA) to provide more clarity about its regulatory approach to digital health technologies (DHTs), as well as for greater flexibility in their use in clinical trials.